This clinical trial is focused on studying a skin condition called Generalized Epidermolysis Bullosa Simplex (EBS). EBS is a rare genetic disorder that causes the skin to be very fragile, leading to blisters and wounds from minor injuries or friction. The study is testing a treatment called Diacerein 1% Ointment, which is applied directly to the skin. Diacerein is a chemical substance that may help reduce inflammation and improve skin healing in people with EBS.

The purpose of the study is to evaluate how effective and safe the Diacerein 1% Ointment is for treating EBS. Participants in the study will be randomly assigned to receive either the Diacerein ointment or a vehicle ointment, which is a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The study will last for several weeks, during which participants will apply the ointment to their skin and attend regular check-ups to monitor their progress and any side effects.

Throughout the study, participants will be asked to report any changes in their symptoms, such as pain or itching, and any other health issues they experience. The study aims to determine if the Diacerein 1% Ointment can successfully reduce the severity of EBS symptoms and improve the quality of life for those affected by this condition. Participants will also have the opportunity to continue using the ointment in an open-label extension phase, where everyone will receive the actual treatment, to further assess its long-term benefits and safety.